TOT BIOPHARM International (HKG:1875) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥1.10b (up 41% from FY 2023).
- Net income: CN¥34.8m (up from CN¥37.8m loss in FY 2023).
- Profit margin: 3.2% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
- EPS: CN¥0.048 (up from CN¥0.052 loss in FY 2023).
1875 Products In Clinical Trials
- Phase III: 1.
1875 Post-Clinical Trial Products
- Pre-registration: 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
TOT BIOPHARM International Earnings Insights
The primary driver behind last 12 months revenue was the Mainland China segment contributing a total revenue of CN¥1.08b (99% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to CN¥606.7m (81% of total expenses). Explore how 1875's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in Hong Kong.
Performance of the Hong Kong Biotechs industry.
The company's shares are down 6.9% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of TOT BIOPHARM International's balance sheet and an in-depth analysis of the company's financial position.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.